CBM News Alert Cambrex Corp (CBM) 21.62 12/25/2014 12:44:57

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Cambrex Corp (CBM) 21.62 $CBM

22.2% Return Seen to Date on SmarTrend Cambrex Call (CBM)
Comtex SmarTrend(R) - Thu Dec 18, 9:54AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 months, Cambrex has returned 22.20% as of today's recent price of $23.53.
CBM: 21.62 (+0.37)

United States Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry Analytics 2014-2021 - Market to reach $21.2 billion by 2021
M2 - Mon Dec 15, 8:28AM CST
Research and Markets (http://www.researchandmarkets.com/research/b7xlml/vitamins) has announced the addition of Plunkett Research Ltd's new report "Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.): Analytics, Extensive Financial Benchmarks, Metrics and Revenue Forecasts to 2021" to their offering. Vitamins, Botanicals, Nutritional Supplements and Medicinal Chemicals Manufacturing Industry (U.S.) to reach $21.2 billion by 2021. Vital industry-specific data including metrics, benchmarks, historic numbers, growth rates and forecasts that will save countless hours of research. Core Benefits to Customer: 1. Comprehensive overview of an industry's financial results, ratios, vital statistics and metrics in one package 2. Complete benchmarking of the industry and its top companies 3. Deep industry and company financials This Report Features: 1. Historical data 2. Revenue forecasts, growth rates and CAGR 3. Operating ratios 4. Complete data for benchmarking a company to its industry and to specific leading companies 5. Benchmarking this industry to all U.S. industries 6. Deep profiles and financial histories/operating ratios for up to ten top U.S.-based companies Designed to benefit: - Analysis and Financial Modeling - Investment Professionals - Lenders - M&A Advisors - Appraisers - Consultants Key Data: Industry Summary - Revenues historical through 2013 - Revenues projected through 2021 - Employee Count 2007-2013 - Annual Growth Rate 2013 - CAGR 2006 through 2013 - CAGR 2014 through 2021 - Top U.S. Companies Employment and Establishments - Number of Firms 2007-2013 - Number of Establishments 2007-2013 - Employees, 2007-2013 - Average Annual Sales per Firm & per Establishment 2007-2013 - Sales per Employee Average Annual Operating Ratios - Revenue Compared to All Industries - Expenses Compared to All Industries - Profits & Income Taxes Compared to All Industries Benchmarks This Industry Compared to All Industries - Comparison of Revenues, Profits and Taxes to All Industries Industry Results, Publicly-Held Companies (U.S.), Average for all Companies - Industry Income Statement, Balance Sheet, Cash Flow Statement, 2008-2013 Top Companies Profiled & Ranked In-Depth Profiles, Financial Reports, Ranks & Executive Lists for Top U.S.-Based Corporations Top Companies Ranked - Market Capitalization - Employees - Revenue - Net Income - 3-Year Revenue Growth - 3-Year Income Growth - Return on Assets - Return on Equity - Return on Invested Capital List of Leading (Public and Private) Companies - Aceto Corporation - Balchem Corp - Cambrex Corp - Mannatech Inc - Mead Johnson Nutrition Company - NBTY Inc - Schiff Nutrition International Inc - Sigma-Aldrich Corp - Synutra International, Inc. - USANA Health Sciences Inc For more information visit http://www.researchandmarkets.com/research/b7xlml/vitamins Source: Plunkett Research Ltd
ACET: 21.85 (-0.07), MJN: 102.04 (+0.48), CBM: 21.62 (+0.37), SIAL: 137.16 (-0.01), USNA: 103.51 (+0.91), SYUT: 5.20 (+0.07), MTEX: 28.96 (unch), BCPC: 66.80 (-1.55)

Uptrend Call Working As Cambrex Stock Rises 22.0% (CBM)
Comtex SmarTrend(R) - Thu Dec 11, 9:37AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 21.99% as of today's recent price of $23.49.
CBM: 21.62 (+0.37)

Cambrex To Present At Oppenheimer 25th Annual Healthcare Conference
PR Newswire - Thu Dec 04, 12:40PM CST
Cambrex Corporation (NYSE: CBM, "Cambrex" is pleased to announce that Steven M. Klosk, President and Chief Executive Officer, will present at the Oppenheimer 25th Annual Healthcare Conference on December 11, 2014 at 8:00 a.m. EST, in New York City.
CBM: 21.62 (+0.37)

Shares of CBM Up 19.9% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Dec 03, 4:58PM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 1 month, Cambrex has returned 19.86% as of today's recent price of $23.08.
CBM: 21.62 (+0.37)

Cambrex Shares Up 19.0% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 26, 11:12AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 4 weeks, Cambrex has returned 19.03% as of today's recent price of $22.92.
CBM: 21.62 (+0.37)

Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020 for the $190 Billion Industry
M2 - Thu Nov 20, 6:03AM CST
Research and Markets (http://www.researchandmarkets.com/research/sm7qx5/global_active) has announced the addition of the "Global Active Pharmaceutical Ingredients Market - Trends & Forecast to 2020" report to their offering. The global Active Pharmaceutical Ingredient market is expected to reach a market size approximately $190 billion by 2020, growing at a CAGR of more than 6.5% from 2014 to 2020 API market is mainly driven by the factors such as patent expiration of major drugs, increased generic medicine sales and high uptake of biologics. High Potential Active Pharmaceutical Ingredients (HPAPI) are also driving the API market growth globally as these compounds are very effective in treatment of diseases such as cancer, respiratory disorders and hormonal imbalances and HPAPI growth is mainly driven by its therapeutic applications in Oncology. Depending on the product type the API market is segmented into synthetic API, Biotech API, and HPAPI. Synthetic API commanded the largest share in 2013 and is growing at a steady pace, whereas the biotech API is expected to register the highest CAGR during the forecast period, strongly driven by the monoclonal antibodies and recombinant proteins. Depending on the applications the API market is categorized into oncology, cardiovascular and hematopoietic system, central nervous system, anti-infective, gastrointestinal, respiratory system, metabolic disorders, genito-urinary disorders, and others. Cardiovascular commanded the largest share of more than 40% in 2013 and is growing at a steady pace, whereas oncology is expected to register the highest CAGR during the forecast period. HPAPI commanded the largest share in the oncology application segment in 2013 and is growing at a highest CAGR in the anti-infectives segment. Scope of the Report Global API Market, by Synthesis: - Synthetic Chemical API - Branded/Innovative - Generic/Non-branded - Biotech API - Biologics - Biosimilars - Mammalian cell culture - Monoclonal antibodies - Recombinant proteins - Vaccines - Insulin analog - Growth hormone manufacturing - Interferon manufacturing - HPAPI Global API Market, by Business type: - Captive - Merchant Global API Market, by Therapeutic Applications: - Anti-infectives - Oncology - Cardiovascular and hematopoietic system - Central nervous system - Respiratory system - Gastrointestinal disorders - Hormone-related disorders - Metabolic disorders - Genitourinary disorders - Musculo-skeletal disorders - Others Companies Mentioned - Albemarle Corporation - Aurobindo - Boehringer Ingelheim GmbH - Cambrex Corporatio - Dr. Reddy's Lab - Lonza Group - Lupin - Novartis - Ranbaxy Laboratories - Teva Active Pharmaceutical Industries Limited For more information visit http://www.researchandmarkets.com/research/sm...bal_active
CBM: 21.62 (+0.37), ALB: 60.48 (-0.34), NVS: 93.91 (+0.66)

Cambrex Earnings Review: 18 Days after Announcement Shares Up 11.1% (CBM)
Comtex SmarTrend(R) - Mon Nov 17, 10:50AM CST
18 days ago, on October 30th, 2014, Cambrex (NYSE:CBM) reported its earnings. Analysts, on average, expected earnings of $0.26 per share on sales of $94.2 million. The company actually reported EPS of $0.26 on sales of $81.3 million, beating EPS estimates by $0.00 and missing revenue estimates by $12.9 million. Shares of Cambrex have climbed from $20.86 to $23.17, representing a gain of 11.1% since the company reported earnings 18 days ago.
CBM: 21.62 (+0.37)

Cambrex Shares Up 20.2% Since SmarTrend's Buy Recommendation (CBM)
Comtex SmarTrend(R) - Wed Nov 12, 9:19AM CST
SmarTrend identified an Uptrend for Cambrex (NYSE:CBM) on October 28th, 2014 at $19.26. In approximately 2 weeks, Cambrex has returned 20.18% as of today's recent price of $23.14.
CBM: 21.62 (+0.37)

Can the Rally in Cambrex (CBM) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Nov 07, 7:34AM CST
Can the Rally in Cambrex (CBM) Shares Continue?
CBM: 21.62 (+0.37)

NYSE stocks posting largest percentage increases
AP - Tue Nov 04, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage gainers on New York Stock Exchange at the close of trading:
DHX: 10.28 (+0.08), HLF: 37.98 (+0.20), CBM: 21.62 (+0.37), ESI: 10.18 (-0.01), JMP: 8.08 (-0.24), THR: 23.68 (+0.12), AU: 8.39 (+0.24), VSLR: 8.97 (+0.18), NLS: 14.58 (-0.17), CCG: 7.58 (-0.05), DAC: 5.50 (-0.03), CVD: 103.73 (+0.02)

Cambrex's (CBM) CEO Steve Klosk on Q3 2014 Results -- Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Sun Nov 02, 1:36AM CDT

CBM: 21.62 (+0.37)

Cambrex posts 3Q profit
Automated Insights - Thu Oct 30, 8:42AM CDT
E RUTHERFORD, N.J. (AP) _ Cambrex Corp. (CBM) on Thursday reported net income of $8.8 million in its third quarter.
CBM: 21.62 (+0.37)

Cambrex (CBM) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Thu Oct 30, 7:25AM CDT

CBM: 21.62 (+0.37)

Cambrex beats by $0.02, misses on revenue
Seeking Alpha - at Seeking Alpha - Thu Oct 30, 6:27AM CDT

CBM: 21.62 (+0.37)

Cambrex Reports Third Quarter 2014 Financial Results
PR Newswire - Thu Oct 30, 6:00AM CDT
Cambrex Corporation (NYSE: CBM) reports results for the third quarter ended September 30, 2014.
CBM: 21.62 (+0.37)

Notable earnings before Thursday’s open
Seeking Alpha - at Seeking Alpha - Wed Oct 29, 4:30PM CDT

FIS: 63.62 (-0.42), HST: 24.23 (-0.07), CRR: 40.16 (-0.81), CAH: 82.07 (+0.15), AMT: 100.75 (+0.10), ACIW: 20.76 (+0.12), GTI: 4.84 (-0.04), IDA: 67.37 (+1.01), CRCM: 8.12 (+0.14), CVRR: 16.90 (-0.21), BGCP: 9.06 (-0.10), GOV: 23.32 (-0.03), DFT: 33.68 (+0.03), APO: 23.33 (-0.09), FIG: 7.89 (unch), AMAG: 43.02 (+0.90), HAR: 105.30 (+0.11), AVP: 9.22 (-0.07), EXLS: 28.69 (+0.21), INGR: 86.09 (-0.27), ALU: 3.67 (+0.03), INCY: 71.57 (+1.99), COP: 70.13 (-0.92), GEL: 43.39 (-0.65), COR: 38.83 (+0.43), GTLS: 34.61 (+0.14), BWA: 55.67 (-0.72), CARB: 14.54 (+0.94), GLOP: 25.07 (-0.23), IDCC: 54.33 (+0.15), HEES: 28.38 (-0.59), BCO: 24.09 (-0.03), DST: 95.96 (-0.16), EPD: 35.45 (+0.25), ABMD: 38.46 (+0.13), CEVA: 18.37 (+0.56), BLL: 69.70 (-0.14), GBX: 51.59 (+0.47), GNC: 46.10 (-0.29), CVI: 39.62 (unch), ACOR: 39.14 (+0.74), I: 16.83 (+0.19), FCN: 39.23 (-0.16), CRNT: 0.98 (+0.02), DHX: 10.28 (+0.08), BG: 92.03 (-0.33), CME: 90.58 (-2.14), FCH: 10.80 (-0.06), ALLE: 55.73 (+0.05), AUDC: 4.51 (+0.01), APD: 148.58 (unch), DBD: 35.55 (-0.05), HGG: 7.65 (-0.12), CBM: 21.62 (+0.37), CNSL: 28.07 (+0.32), ATK: 113.52 (+0.59), ANR: 1.60 (-0.02), CI: 104.23 (-0.08), ABC: 91.60 (+0.18), GG: 17.67 (+0.49)

Cambrex to Announce Third Quarter 2014 Financial Results on October 30, 2014
PR Newswire - Tue Oct 28, 2:03PM CDT
Cambrex Corporation (NYSE: CBM) announced that third quarter 2014 financial results will be released on Thursday, October 30, 2014 before the market opens.
CBM: 21.62 (+0.37)

Shares of CBM Down 10.6% Since Downtrend Call on Shares
Comtex SmarTrend(R) - Wed Oct 22, 11:22AM CDT
SmarTrend identified a Downtrend for Cambrex (NYSE:CBM) on September 23rd, 2014 at $19.89. In approximately 4 weeks, Cambrex has returned 10.61% as of today's recent price of $17.78.
CBM: 21.62 (+0.37)




Scroll down for more posts ▼

Top 10 Most Recent News Articles

ECW Puts $52 Million Behind Learning Through Crisis

Updated Category News Views 66

A reserve fund for a classroom is not glamorous, but it may be the smartest detail in this whole $52 million commitment. Education Cannot Wait has announced support for more than 300,000 children in Lebanon, Myanmar and South Sudan, where war, flooding and displacement have ripped ordinary schooling apart. The money is meant to restore learning, provide catch-up classes...

Continue Reading
Kyverna Probe Reopens IPO Disclosure Questions for Investors

Updated Category News Views 22

Clinical-trial caveats have a nasty habit of becoming shareholder headaches years later. Kyverna Therapeutics is back in that uncomfortable zone after Kahn Swick & Foti said it has opened an investigation into whether the company’s officers and directors breached fiduciary duties or otherwise violated state or federal law. For holders of KYTX, this is not a verdict and...

Continue Reading
YYForce Security Win Adds Recurring Singapore Revenue Base

Updated Category News Views 160

A retail-property security mandate rarely makes anyone pound the table, and frankly it should not. Still, YYForce has landed a tangible two-year contract in Singapore worth roughly S$831,120, with subsidiary Uniforce Security Services set to begin work on December 1, 2026. For NASDAQ:YFOR investors, this is the kind of small, operationally real win that deserves a sober...

Continue Reading
ASA’s 2026 Grants Push Dermatology Into New Terrain

Updated Category News Views 58

Thirteen Small Bets With Serious Human Stakes Skin science rarely gets the splashy headlines, yet it touches a staggering number of people and carries some very stubborn unanswered questions. American Skin Association’s 2026 grant class puts 13 awards across skin cancer and dermatologic disease, with a noticeable willingness to follow newer clinical terrain rather than...

Continue Reading
Niron's $1.8B Alabama Bet Carries Big Magnet Stakes

Updated Category News Views 54

A Huge Factory Claim Needs More Than Applause A magnet company just tossed a very large number onto Alabama's economic-development table. Niron Magnetics says it plans a $1.8 billion investment in the state that would create 700 jobs. That is not pocket change, not a ribbon-cutting trinket, and not the sort of announcement investors should breeze past between earnings...

Continue Reading
Appian Survey Flags AI Aloneware Maintenance Drag Risk

Updated Category News Views 58

A bot can spit out a feature before lunch, then leave a repair bill nobody budgeted for. That is the uncomfortable issue behind Appian's new research on AI-assisted software development: speed is easy to celebrate, while ownership gets shoved into a dark corner until something breaks. Appian said on November 20, 2026, that two-thirds of surveyed AI decision-makers and IT...

Continue Reading
Sogroya Approval Broadens Novo's Pediatric Growth Franchise

Updated Category News Views 75

Seven fewer injections every week is the real headline behind Novo Nordisk's latest FDA clearance, not some flashy efficacy leap. On November 20, 2026, the company said Sogroya, its once-weekly long-acting growth hormone, won approval for children aged 2.5 and older with growth failure associated with Turner syndrome. That matters because treatment can stretch over years,...

Continue Reading
PCS Rental Prep Is About Control Before Distance Hits

Updated Category News Views 82

A vacant house can turn into a long-distance headache with startling speed. For military homeowners preparing for a PCS move, the useful point in Rhonda Leahy's guidance is not glamorous: settle the boring operational stuff before the moving boxes, travel orders, and new-duty-station chaos swallow the calendar. Renting out a former home is not merely collecting enough...

Continue Reading
Mobile Core's Cost Crunch Favors Telecom's Big Three

Updated Category News Views 67

Server bills have finally crashed the party in mobile core, and nobody should pretend that is a minor inconvenience. Dell'Oro Group's 3Q 2026 read is blunt: Mobile Core Network revenue growth was lackluster because 5G spending came in below expectations, while higher server costs pushed operators to reshuffle priorities, postpone projects, and keep 4G core gear alive...

Continue Reading
Why Brief Chiropractic Visits Still Need Clear Expectations

Updated Category News Views 76

A few minutes on the table can sound almost suspiciously brisk when somebody is dealing with a stiff neck, sore back, or nagging joint discomfort. Yet that is the central point in Dr. Craig Peterson's explanation for HelloNation: the adjustment itself may be brief, while the value of a chiropractor visit depends on a focused assessment, appropriate technique, and whether...

Continue Reading

Top 5 Most Recently Viewed Articles

Organon & Co. Class Action Lawsuit: Key Details You Should Know

Updated Category News Views 221

Overview of the Class Action Lawsuit Against Organon & Co. The latest developments in the class action lawsuit regarding Organon & Co. (NYSE: OGN) have attracted attention from investors. The lawsuit is aimed at representing purchasers of Organon's publicly traded securities during a specific time frame. Robbins Geller Rudman & Dowd LLP has taken the lead in filing this...

Continue Reading
JINRO Partners with BTS's V: A Strategic Move

Updated Category News Views 25

What's Brewing Between JINRO and BTS's V? Picture this: you're wandering the aisles of an international market, see a splashy new bottle of soju, and notice V from BTS smiling from the label. That's right, folks, JINRO, the world's reigning soju brand, has just snagged a partnership with BTS's V to serve up a global brand punch. This move isn't just a pretty face on a...

Continue Reading
Latin Metals Unveils Exciting Spin-Out Plan for Copper Assets

Updated Category News Views 172

Latin Metals Moves Forward with Spin-Out of Peruvian Assets Latin Metals Inc. (TSXV: LMS, OTCQB: LMSQF) is charting a new course by announcing its decision to spin-out certain Peruvian exploration projects into a newly founded subsidiary named Latin Explore. This strategic move aims to unlock value for shareholders while maintaining a robust exploration agenda. Overview...

Continue Reading
McCormick's Resilience Shines Amidst Economic Challenges

Updated Category News Views 66

McCormick Challenges and Growth Strategy McCormick & Company, Inc. (NASDAQ: MKC) recently announced its third-quarter earnings, revealing a solid financial performance, even in a tough consumer environment. The company achieved a 1% volume growth in its Consumer segment and steady sales in its Flavor Solutions segment, showcasing a strong market presence despite...

Continue Reading
Goodyear's Financial Performance Amidst Industry Challenges

Updated Category News Views 248

Understanding Goodyear's Recent Earnings Report Goodyear Tire & Rubber Co (NASDAQ: GT) has reported its recent financial results, particularly highlighting the challenges faced during the second quarter of their fiscal year 2025. This period proved to be quite turbulent after the closing bell, reflecting considerable disruptions in their operating environment that...

Continue Reading